Search Results for “Alzheimer's” – media

$1.4 billion deal highlights the future of Alzheimer’s disease therapy

The development of therapies for Alzheimer’s disease has always caused many developers to feel exhausted, and now AbbVie has also increased its investment in neurodegenerative diseases. AbbVie has agreed to spend $1.4 billion to acquire Aliada Therapeutics, whose main acquisition asset is Aliada’s authorized Alzheimer’s disease candidate drug ALIA-1758 from Johnson&Johnson. Its mechanism of action is still an anti beta amyloid protein (3pE-A β) antibody, but the unique feature of ALIA-1758 is that it can cross the blood-brain barrier, greatly improving the brain’s absorption rate. Aliada started a phase 1 trial among healthy volunteers in May, but AbbVie believes the timing is ripe for acquisition. Previously, AbbVie made the decision to abandon its internal Alzheimer’s disease asset ABBV-916. This anti beta amyloid antibody has no significant difference in safety and efficacy compared to the already marketed monoclonal antibody therapy for Alzheimer’s disease. Therefore, AbbVie decided to terminate the development ...
- Source: drugdu
- 57
- November 5, 2024
Just now! The first Chinese generic version of the “blockbuster Alzheimer’s drug” was released

On September 25, NMPA released information on the delivery of drug certification documents, and the rivastigmine transdermal patch of Beijing Taide Pharmaceutical Co., Ltd. (hereinafter referred to as “Tide Pharmaceutical”), a subsidiary of Sino Biopharmaceutical, was approved for marketing. It is understood that the drug can be used to treat mild to moderate Alzheimer’s disease. Forecasts of the development trend of Alzheimer’s disease and other forms of dementia in China show that in 2030, 2040 and 2050, the number of AD patients in the population aged 60 and above in China will reach 19.11 million, 24.71 million and 27.65 million respectively. Under the influence of multiple factors such as the accelerated aging trend of the population in China and the increasing prevalence of major cardiovascular diseases and related factors, the prevalence and number of patients with Alzheimer’s disease have also shown an increasing trend year by year. Rivastigmine is an ...
- Source: drugdu
- 68
- September 28, 2024
Blood Test Predicts Alzheimer’s Disease with Over 90% Accuracy

Alzheimer’s disease impacts one in five women and one in ten men over their lifetimes, yet diagnostic tools are still often cumbersome and not widely accessible in primary care settings. Although specialized memory clinics frequently use advanced diagnostic methods like PET scans and cerebrospinal fluid tests, there is a significant need for simpler, quicker diagnostic tools that can be used in primary care. Now, a commercially available blood test for Alzheimer’s has demonstrated approximately 90% reliability in primary care settings, representing a major development for individuals seeking assistance for memory loss and suspected of having this neurological disease. Research on this innovative blood testing method, which evaluates levels of Plasma Phospho-Tau217, commenced in 2019 with studies showing that the blood test can detect Alzheimer ‘s-related changes even before symptoms appear and monitor the disease’s progression. Earlier this year, results indicated that this blood test is as reliable as, and ...
- Source: drugdu
- 121
- August 1, 2024
Advanced Blood Test to Spot Alzheimer’s Before Progression to Dementia

Alzheimer’s disease is well known for its slow development over many years, which typically leads to treatment interventions only after the disease has advanced to stages where it may be nearly impossible to slow down its progression. The results of a groundbreaking study, recently published in the journal Nature Communications, have offered new hope for not only earlier diagnosis but also for potentially slowing the course of Alzheimer’s disease. A team of researchers from Aarhus University (Aarhus, Denmark) has identified a specific receptor found on immune cells that can bind and neutralize harmful “beta proteins”, which are closely linked with the development of Alzheimer’s disease. The study underscores the significant role that the peripheral immune system may play in defending the body against Alzheimer’s by preventing the build-up of these harmful proteins in the brain. This discovery paves the way for detecting the disease-related changes much earlier than current methodologies ...
- Source: drugdu
- 116
- May 10, 2024
$770 Million! AriBio authorizes Marketing Rights for a Drug to Treat Alzheimer’s Disease in China

It’s reported according to businesswire, AriBio recently announced that it has signed a licensing agreement for the exclusive marketing rights of AR1001, an investigational drug for the treatment of early Alzheimer’s disease, in China at a price of up to US$770 million. Considering the market competition and sales strategy of Alzheimer’s disease drugs in China, the licensee requested that no disclosure be made until the agreed time. The agreement includes an upfront non-refundable payment of 120 billion won (approximately US$90 million), with a total transaction value of up to 5.59 billion yuan (approximately US$770 million), including milestone payments and additional royalties. Upfront payments will begin in mid-2024. AR1001 is a phosphodiesterase type 5 (PDE5) inhibitor in development and an investigational oral drug for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed that AR1001 can inhibit neuronal apoptosis and restore synaptic plasticity, thus having neuroprotective effects. AR1001 also demonstrated a ...
- Source: drugdu
- 143
- March 28, 2024
Groundbreaking pTau217 Blood Test as Accurate as Brain Imaging or CSF Testing in Diagnosing Alzheimer’s

Alzheimer’s disease (AD) is a neurodegenerative condition that causes the brain to deteriorate over time, marked by the buildup of certain harmful proteins that eventually lead to a decline in brain function and cell death. These changes can happen long before any symptoms show up. Scientists have found certain proteins in the cerebrospinal fluid that are good indicators of AD. One of the most promising markers for early and more precise detection of AD in the blood is phosphorylated tau at position 217 (pTau217). It’s seen as a game-changer for diagnosing AD sooner, categorizing patients for research studies, and improving how patients are cared for and treated. Now, an innovative and novel blood test can be used in the screening, diagnosis, and monitoring of AD based on the circulating level of this promising biomarker pTau217. ALZpath Dx (Carlsbad, CA, USA) has developed a robust and scalable plasma-based ultra-sensitive assay, branded ...
- Source: drugdu
- 152
- March 23, 2024
Cerebrospinal Fluid Testing of Alzheimer’s Patients to Help Identify Disease Molecular Subtype

Scientists have made a significant discovery by identifying five distinct biological variants of Alzheimer’s disease, each potentially requiring unique therapeutic approaches. This finding suggests that drugs previously tested for Alzheimer’s might have been wrongly deemed ineffective or only slightly beneficial due to these variants being unaccounted for. At the core of Alzheimer’s disease is the accumulation of amyloid and tau proteins in the brain. However, this aggregation is just one aspect of the disease’s complexity. Researchers, including those from Amsterdam UMC (Amsterdam, Netherlands), have employed innovative methods to analyze additional biological processes involved in Alzheimer’s. These processes, which include inflammation and the growth of nerve cells, were studied through the measurement of various biomarkers in the cerebrospinal fluid of patients exhibiting amyloid and tau accumulations. In their analysis of the cerebrospinal fluid of 419 individuals diagnosed with Alzheimer’s, the researchers assessed 1,058 proteins and identified five distinct biological subtypes within ...
- Source: drugdu
- 169
- January 17, 2024
Stem-cell-derived brain cells hold promise for Alzheimer’s, Parkinson’s research

Researchers at the University of Wisconsin–Madison have identified a protein key to the development of a type of brain cell believed to play a role in disorders like Alzheimer’s and Parkinson’s diseases and used the discovery to grow the neurons from stem cells for the first time. The stem-cell-derived norepinephrine neurons of the type found in a part of the human brain called the locus coeruleus may enable research into many psychiatric and neurodegenerative diseases and provide a tool for developing new ways to treat them. Yunlong Tao, an investigator at Nanjing University in China who was a research professor at UW–Madison’s Waisman Center when the study was performed, and Su-Chun Zhang, a UW–Madison professor of neuroscience and neurology, published their work on the cells, which they call LC-NE neurons, today in the journal Nature Biotechnology. Norepinephrine neurons in the locus coeruleus regulate heartbeat, blood pressure, arousal, memory, attention and ...
- Source: drugdu
- 113
- November 21, 2023
Photobiomodulation in sleep has more therapeutic effects for Alzheimer’s disease than in wakefulness

It is well known that sleep is the best medication. However, it is still unknown why the brain recovers better in sleep and whether these processes can be controlled. Recent discoveries have shown that the lymphatic system of the brain is activated during sleep, which contributes to the removal of metabolites, toxins and unnecessary molecules from its tissues. Sleep disturbance contributes to the deposition of metabolites in the central nervous system (CNS). For example, sleep is a biomarker for the development of Alzheimer’s disease. This is due to the fact that the toxic metabolite beta-amyloid is excreted from brain tissue during sleep. Sleep deprivation leads to the accumulation of toxin in the CNS, which over time can lead to the development of Alzheimer’s disease. In this pilot study, the researchers have shown that non-invasive sleep photobiomodulation technology can effectively increase lymphatic excretion of beta-amyloid from the brain tissues of mice ...
- Source: drugdu
- 213
- September 25, 2023
Muscle-Building Supplement May Help Protect Memory and Prevent Alzheimer’s Disease

The secret to protecting your memory may be a staple of a bodybuilder’s diet. RUSH researchers recently discovered that a muscle-building supplement called beta-hydroxy beta-methylbutyrate, also called HMB, may help protect memory, reduce plaques and ultimately help prevent the progression of Alzheimer’s disease. HMB is not a prescription drug or a steroid, but an over-the-counter supplement that is available in sports and fitness stores. Bodybuilders regularly use HMB to increase exercise-induced gains in muscle size and strength while improving exercise performance. HMB is considered safe even after long-term use, with no known side effects. “This may be one of the safest and the easiest approaches to halt disease progression and protect memory in Alzheimer’s disease patients,” said Kalipada Pahan, PhD, the Floyd A. Davis, MD, Professor of Neurology and professor of neurological sciences, biochemistry and pharmacology at RUSH Medical College. Studies in mice with Alzheimer’s disease ...
- Source: drugdu
- 204
- July 24, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.